



Can Keep Them "Happy For Life"

By Treating The Root Causes of Depression

Indication: Clinical Dietary Management of Major Depressive Disorder

Once-a-day dosing / No age restriction

TEAM METHYLATION

PRE-METABOLIZED COENZYMES AND COFACTORS BRAIN READY INGREDIENTS

L-Methylfolate Magnesium	7mg
Folinic Acid	2.5mg
DHF	1mg
B12 (Adenosylcobalamin)	50mcg
B6 (Pyridoxal-5-Phosphate)	25mcg
B1 (Thiamine Pyrophosphate)	25mcg
B2 (Flavin Adenine Dinucleotide)	25mcg
B3 (Nicotinamide Adenine Dinucleotide)	25mcg
PS-Omega-3 (Phosphatidylserine, EPA, DHA)	20mg
Magnesium Ascorbate	24mg
Magnesium L-Threonate	1mg
Iron	1.5mg
Zinc Ascorbate	1mg
Betaine	500mcg
Citric Acid Monohydrate	1.83mg
Sodium Citrate	3.67mg
CoQ10	500mcg
Piperine (B Vitamin Bioenhancer)	500mcg

CNS Biochemical Actions

- 1. Normalizes and balances Neurotransmitter production (serotonin, dopamine, norephinephrine, epinephrine and GABA)
- 2. Normalizes production of endogenous SAM-E for methylation of DNA, RNA, proteins and lipids
- 3. Normalizes Glutathione production
- 4. Reduces High Homocysteine

Methylation Chart

ENL/EnLyte, EnBrace HR Product Ingredients Maroon

Normalizes all co-enzyme/cofactor deficiencies no matter what the cause and converts to clinical wellness based on well controlled clinical trials.



 2) Acute treatment of MDD in women who were depressed and wanted to avoid the use of an 	
chool of Theoremsant or did not wait to increase the task of the transfer were already taking.	at
MA baseline experienced a relapse to an MDE (27.3%), a rate lower than expected when compared to nistorical controls who dividentiated and depress at for A error (6, 7%).	
• All participants in Group 1, who were repressed at baceling experienced remasized by the end of the Surgerman (1, 2), 6 (Set 3-1) experienced over a 50% in provement on the MABRS from baseline. Dre part	ient
 in Group 2 remitted, then relapsed, then again remitted prior to completing the study. We found EnBrace HR was well-tolerated in this separate for serious adverse event occurred; a womar 	n in
Group 1 experienced a relapse of depression and was hospitalized. Correlation of Clinical Response With Homocysteine Reduction During Therapy With EnLyte/EnBrace	HR
 Strengtins in Patients With MDD Who Are Positive for MTHFR C6//j(<u>Gr</u>A)1298C Polymorphism Westisstessed a novel nutritional supplement for MDD prevention and treatment in women in the anter Courts and pasel congestion 	natal
 Difficulty concentrating Other strength Other strengt Other st	e
ADULT PATIENT RANDOMIZED DOUBLE	
Abdomina Limitations • Elsepered to Controlled Study	_
 Mechanical fa. General fa. General failed in the second second	_
O BUT TO THE SEPARATE STATES THE STATES THE STATES THE STATES AND THE SEPARATE	l. It is
En with major provide the second terms in adults with major depressive disorder	_
Study results suggest EnBrace HR is a novel and well tolerated intervention with potential efficacy for t (Morevention Party freetine is the provident of the p	<u>he</u> SIS
that EnLyte/EnBrace HR will lower homecysteine majority of clinical responding of treatments for antenatal depression.	ng
Results Summary	aha
• 1) Prevention of depressive relapse in women with histories of MDD Kessler B.C. Endeminlary of women and depression. Laffert bisord 2003, 74(1) double	Ode
. Noble, R22 A cutto, treatmont aboli MaDsins wome n who were depressed and wanted to avoid the use of an Cohen, LS, et al., Relapse of major depression during pregnancy in women who inpintain or discontinue antidepressant treatment. Jana, 2006, 295(5), p. 499-507. Andrade 3.1. Were Discontinue antidepression during pregnancy in women who inpintain or discontinue antidepressant treatment. Jana, 2006, 295(5), p. 499-507.	
 Lumatically a. of all felt reported period depressive switching and period and period and period depression scale. Clin Epidemip/ 3988. 10: p. 655-669. Usaschingesexperiod and the faither and the section and MDEA (2016) 7655-669. Usaschingesexperiod and the section and th	E s 12
MERELOCICE LCORNELED & AND CONSCIPTION BALL AND CONSCIPTION CONSCIPLICACICULAR CONSCIPTION CONSCIPTION CONSCIPLICO	udies and 7-140.
Aller Lidy ean or Biori B	nt
3.sa MS, F., Watt, Adjunctive Watt & entited by of beyYestbn: A Strainbackeview with mediate a worthan in the mediate by the set of the frequencies of the frequencie	JIII
2. Kelta C.B., et al., <i>Iberdari</i> Endevites in social de objecto fonde and containing endevine and containing endevine e	71.
16912): 51267242 C CHIEVEN ACTION CONTROL SUPPLY AND CONTRUCT SUPPLY AND CONTROL SUPPLY AND CONTROL SUPPLY A	
13. Passen, M. et al., Oroles' methylitetrahydrofolic ocid in senile organic mental disolders with Reveal (A) 1993 10 19 19 19 19 19 19 19 19 19 19 19 19 19	ıl 2013.
15(4). 15. Roffman, J.L., Neuroprotective Effects of Prenatal Folic Acid Supplementation: What Timing I Chia Chia Chia Chia Chia Chia Chia Chia	N
Compared to Placebo β ΓΙΔΟΕΟΟ ΓΙΔΟΕΟΟ depressive relapse and symptom burden ³ . Concurrent parallel comparison groups were not available.	р. р.
NO SIDE EFFECT WAS REPORTED AT GREATER RATE THAN PLACEBO	
Marlene P. Freeman: National Pregnancy Registry for Atypical Antipsychotics Research Support: Alkermes Biopharmaceuticals, Forest/Actavis Ph	5
ONSET OF ACTION 2 WEEKS	e one;
prevention and treatment of depression among women planning pregnancy and who are pregnant wee Eargen controlled analy meshe to stange do definitively elected from reffilerors and bits indevine the grand anteriation of the stange of the sta	m
- real relations of the second s	

MGH

Planning pregnancy/Trying to conceive Pregnant at enrollment 12 (63.2%) 7 (36.9%)

¹ Reproductive Technology (ART) EnBrace HR For The Treatment and Use for conception/attempted conception Prevention of Depression in Women Trying to Conceive and During Pregnancy "Weights during trial Marlene P. Freeman, MD et al, Annals of Clinical Psychiatry Eebruary 2019

Results



symptoms, measured through several mood and quality of life questionnaires. Trends shown by group for the primary mood outcome measure, the MADRS (Montgomery-Asberg Depression Rating Scale) in dark blue; for secondary mood measures, the QIDS–SR (Quick Inventory of Depressive Symptomatology-Self Report) in orange and the EPDS (Edinburgh Postnatal Depression Scale) in light blue; and for a quality of life outcome, the QLESQ-SF (Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form) in green. Group Texperimented ho significant changes in any of the four measures, and Group experienced significant improvements in the mood questionnaires but not the quality of life questionnaire. All ANQYA's indeating significance are reported in Table 3.

Conçlusion:

- 50
- Study results suggest EnBrace HR is a novel and well tolerated $_{0}^{\circ}$ F(6,54)=1.13 p=0.357 F(6,54)=1.83 p=0.111 F(6,54)=1.58 p=0.171 F(2,17)=1.06 p=0.0368 intervention with efficacy for the prevention and treatment of week 12 F(6,29)=5.16 p=0.001 F(6,29)=4.31 p=0.003 F(6,29)=6.49 p=0.0002 F(2,9)=2.88 p=0.108 depression among women planning pregnancy and who are pregnant.

EnLyte and EnBrace HR are indicated as monotherapy or adjunctive therapy as determined by a licensed medical practitioner.

ADJUNCTIVE THERAPY

- Combine with SSRIs or SNRIs from the start to enhance results, reduce dropout rates and for non-responsive patients.
- Augmentation can precede atypical antipsychotic augmentation therapy

APA Guidelines for MDD state: "...Considering the modest evidence that supports folate as an augmentation strategy and its attractive risk-benefit profile, folate can be recommended as a reasonable adjunctive strategy for major depressive disorder that carries little risk..."

MONOTHERAPY PATIENT

- MTHFR Positive
- MTHFR Suspected Based on Family History of:

Mental Illness Addiction Diabetes Miscarriages or Birth Defects Cardiovascular Issues

- Folate depleted based on folate depleting conditions, drugs and population
- To avoid potential side effects of antidepressants
- Before, during and after pregnancy (Pregnancy Category A)
- Addiction Support

CONTRIBUTORS TO FOLATE DEFICIENCY

CONDITIONS	DRUGS	POPULATION
Malabsorption Syndromes	Lamictal	United States: 75% have a form of MTHFR SNP
Digestive Tract Disease	Metformin	
Pregnancy	Methotrexate	
Breast Feeding	Corticosteriods	HIGHER RISK
Kidney Disease	NSAIDs	Hispanic
Liver Disease	Antibiotics	Mediterranean
Cancer	Anticonvulsants	Chinese
Canker Sores	Oral Contraceptives	African American
Alcohol or Drug Abuse	Cholesterol Lowering	
Smoking	Diuretics	
Anemias	H2 Antagonists	
Overcooked Foods		

PATIENTS CAN FEEL COMPLETELY SAFE

Possible Side Effects	EnLyte	SSRI's	SNRI's
Weight Gain	No!	Yes	Yes
Loss of Libido, difficulty achieving erections, inability to reach orgasm	No!	Yes	Yes
Increased thoughts of suicide and aggression in adolescents & adults	No!	Yes	Yes
Drowsiness or Confusion	No!	Yes	Yes
Nervousness & Agitation	No!	Yes	Yes

Phone: 985-629-5825 Website: www.Enlyterx.com We are here to help!

Please call with any questions.

Adapted from: Consumer Reports Best Buy Drugs. Using antidepressants to treat depression: comparing efficacy, safety and price. 2012

HOW TO PRESCRIBE

STEP 1

STEP 2

STEP 3

SUBMIT OUR ELECTRONIC FORM

Visit <u>www.enlyterx.com</u>

- Click "Prescribe Now"
- Fill out the required information
- Click "Submit."

*EnLyte and EnBrace HR will be available in your EMR, but the most cost-effective way to prescribe is by using the "**Prescribe Now**" button. This ensures your patients receive 60 days for just \$60, and the lowest price available moving forward.

INFORM YOUR PATIENT

Let your patient know that a friendly customer care representative will contact them shortly to get started on EnLyte for just \$1 a day for the first 60 days.

WE TAKE CARE OF THE REST

A representative will contact your patient to arrange the initial **60day trial for just \$60**, which will typically be shipped the same day.

REFILLS:

Our Medical Food Distributor will handle all refills to ensure uninterrupted care.



Natural + Safe + Proven

What is EnLyte (ENL)?

EnLyte (ENL) is a small gel cap containing all the brain-ready micronutrients needed to normalize and balance brain chemicals that regulate mood.

TRUSTED BY MEDICAL PROVIDERS NATIONWIDE



People first notice improved energy, focus, concentration & sleep and most begin to feel a difference in about 2 weeks."



www.enlyterx.com

Andrew Farah, MD

Clinically Proven

In one of EnLyte's important published clinical trials, participants with Major Depressive Disorder saw a 75% improvement and 42% remission compared to placebo*.

*Published in the Journal of Clinical Psychiatry, 2016

EnLyte Helps with:

- MTHFR Genetic Issues
- Depressed Mood
- Apathy/Loss of interest
- Anxiety/Worry
- Irritability
- Problems
 Concentrating
- Sleep

Safe Ingredients

EnLyte contains natural ingredients that are generally recognized as safe by the FDA and are gluten-free, dairy-free, wheatfree, sugar-free, egg-free, with no artificial colorants.

Dosing

The recommended dosing is (1) gel cap in the morning, when you wake up (on an empty stomach) or as recommended by your healthcare provider. ENL has No age restriction.



To Order and For a Full List of Ingredients visit: <u>www.enlyterx.com</u>

